BRIEF-Alnylam reports data from ongoing mid-phase open-label study of Patisiran

* Alnylam reports complete 18-month data from ongoing phase 2 open-label extension study of patisiran, an investigational rnai therapeutic targeting transthyretin for the treatment of hereditary attr amyloidosis with polyneuropathy (hattr-pn)